Home Featured Page 76

Featured

Latest

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Pα+ Psychedelic Patent Analysis (October 2023)

PT463 – Bringing Intention, Ceremony, and Inner Healing Intelligence to Modern...

Explore Kanna: A Legal Psychoactive Plant Ally in Turbulent Times

PT462 – Touch Therapy, Wearable Technology, and Treating Trauma with Safety

Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the...

Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic...

Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy Developments

Harming While Healing?: The Oppressive Nature of Psychedelic-Centric Drug Policy

PT461 – Holding Space, Hypnotherapy and Psychedelics, and the Importance of...

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Pα+ Psychedelic Patent Analysis (October 2023)

PT463 – Bringing Intention, Ceremony, and Inner Healing Intelligence to Modern...

Explore Kanna: A Legal Psychoactive Plant Ally in Turbulent Times

PT462 – Touch Therapy, Wearable Technology, and Treating Trauma with Safety

Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the...

Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic...

Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy Developments

Harming While Healing?: The Oppressive Nature of Psychedelic-Centric Drug Policy

PT461 – Holding Space, Hypnotherapy and Psychedelics, and the Importance of...

Pα+ Library: Psychedelic REMS

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY